Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced the voting results ...
New Istaroxime Phase 2b clinical results to be presented by Windtree and top ... Istaroxime is a novel first-in-class therapy that is designed to improve systolic contraction and diastolic relaxation ...